title: Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung).
abstract: Nearly one quarter of patients with lung cancer present with locally advanced disease where concurrent chemoradiotherapy is the current standard of care for patients with good performance status. Cisplatin-based concurrent chemoradiotherapy consistently showed an improvement in survival compared with sequential chemoradiotherapy, at the expense of an increase in the toxicity profile. Over the past decades, several encouraging biomarkers such as transforming growth factor-beta and radioprotective agents such as amifostine were studied but without reaching approval for patient care. We reviewed the prevalence and risk factors for different adverse effects associated with the combined chemoradiotherapy modality, especially dermatitis, mucositis, esophagitis, and pneumonitis. These adverse effects can further be divided into acute, subacute, and chronic. Dermatitis is usually rare and responds well to topical steroids and usual skin care. Acute esophagitis occurs in 30% of patients and is treated with proton pump inhibitors, promotility agents, local anesthetic, and dietary changes. Radiation pneumonitis is a subacute complication seen in 15% of patients and is usually managed with steroids. Chronic adverse effects such as radiation fibrosis and esophageal stricture occur approximately 6 months after completion of radiation therapy and are usually permanent. In this review, complications of chemoradiotherapy for patients with locally advanced lung cancer are delineated, and approaches to their management are described. Given that treatment interruption is associated with a worse outcome, patients are aggressively treated with a curative intent. Therefore, planning for treatment adverse effects improves patient tolerance, compliance, and outcome.
authors.affiliation: Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. yazbeckvy@upmc.edu
authors.forename: Victor Y
authors.initials: VY
authors.lastname: Yazbeck
authors.forename: Liza
authors.initials: L
authors.lastname: Villaruz
authors.forename: Marsha
authors.initials: M
authors.lastname: Haley
authors.forename: Mark A
authors.initials: MA
authors.lastname: Socinski
mesh_terms: D000818:Animals; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects; D004941:Esophagitis / Q000209:etiology / Q000628:therapy*; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D059408:Pain Management; D011832:Radiation Injuries / Q000209:etiology / Q000628:therapy; D017564:Radiation Pneumonitis / Q000209:etiology / Q000628:therapy*; D011855:Radiodermatitis / Q000209:etiology / Q000628:therapy*; D012307:Risk Factors; D013280:Stomatitis / Q000209:etiology / Q000628:therapy